Evidence map›Paper›PMID 34866847›Full record

ArticleJournal of clinical and experimental hepatology

Experience With Changing Etiology and Nontransplant Curative Treatment Modalities for Hepatocellular Carcinoma in a Real-Life Setting-A Retrospective Descriptive Analysis.

Suneel Tohra, Ajay Duseja, Sunil Taneja, Naveen Kalra, Ujjwal Gorsi, Arunanshu Behera, Lileswar Kaman, Divya Dahiya, Srimanta Sahu, Balkrishan Sharma and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. International perspectives on LI-RADS.Abdominal radiology (New York) · 2025
    Review
  5. Article
  6. Review
  7. Abbreviated magnetic resonance imaging in hepatocellular carcinoma surveillance: A review.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024
    Review
  8. Review
  9. The changing epidemiology of hepatocellular carcinoma!Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Article
  10. Multi-center prospective survey of hepatocellular carcinoma in Kerala: More than 1,200 cases.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Systemic Therapies for Hepatocellular Carcinoma in India.Journal of clinical and experimental hepatology
    Review
  17. Review
  18. Article
  19. Article
  20. Treatment for Hepatocellular Carcinoma in South Asia.Journal of clinical and experimental hepatology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Suneel TohraDepartments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Ajay DusejaDepartments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Sunil TanejaDepartments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Naveen KalraRadiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Ujjwal GorsiRadiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Arunanshu BeheraGeneral Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh,160012 India.
Lileswar KamanGeneral Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh,160012 India.
Divya DahiyaGeneral Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh,160012 India.
Srimanta SahuDepartments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Balkrishan SharmaDepartments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Virendra SinghDepartments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Radha K DhimanDepartments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Yogesh ChawlaDepartments of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Post Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) has variable etiological risk factors. Radiofrequency ablation (RFA) and surgical resection (SR) are frequently used as curative treatment options. In the present study, we assessed the etiological factors and efficacy of RFA and SR in patients with unifocal HCC in a real-life setting.

methodsOf 870 patients with HCC seen over a period of nine years, 785 patients were assessed for stage and etiological risk factors. Of these, 110 (14%) patients with single HCC who were either treated with RFA (n = 72) or SR (n = 38) were evaluated for their outcomes in terms of overall survival (OS) and disease-free survival (DFS) over 3 years.

resultsOf 785 patients [median age 60 (range 51-65) years, males (n = 685, 87.3%)] with HCC, viral hepatitis [HBV and HCV with or without alcohol = 502 (63.9%)] was the most common etiology; nonalcoholic steatohepatitis (NASH) and alcohol as an etiology showed increase over the years. About 677 (86.2%) patients had evidence of cirrhosis; NASH and HBV were predominant causes in noncirrhotic patients. Even though the groups were not matched, in 110 patients subjected to either RFA [mean tumor size, 2.2 (1.9-2.8) cm] or SR [mean tumor size, 7.1 (4.8-9.7) cm], tumor progression was observed in 49 (68%) and 16 (42%) patients in RFA and SR groups, respectively, with superior DFS in the SR group (

conclusionViral hepatitis with or without alcohol is the commonest etiological factor for HCC in Northern India; NASH and alcohol are increasing over the years. In a real-life setting, in patients with unifocal HCC, there is no difference in overall 3-year survival subjected to SR or RFA with better DFS in the SR group.

Indexed as

AFP, Alpha FetoproteinalcoholBCLC, Barcelona Clinic Liver CancerCEMR, Contrast-Enhanced Magnetic Resonance ImagingCLD, Chronic Liver DiseaseDFS, Disease-free SurvivalHBV, Hepatitis B VirusHCC, Hepatocellular CarcinomaHCV, Hepatitis C Virushepatitis B virushepatitis C virusLT, Liver TransplantationNAFLD, Non -Alcoholic Fatty Liver DiseaseNASHNASH, Non-alcoholic Steatohepatitisnonalcoholic fatty liver diseaseOS, Overall SurvivalRFA, Radiofrequency AblationSR, Surgical ResectionTPCT, Triple-Phase Contrast-enhanced computerized Tomography

Identifiers

PMID34866847
PMCPMC8617543
OpenAlexW3126909918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.